Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Biogen (NASDAQ: BIIB) will present new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for Alzheimer’s disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Boston, November 1 – 4.
The data include results from patients in the Phase 1b study who were treated with a gradually increased dose of aducanumab for up to 24 months and those who were treated with a fixed dose of 3, 6 or 10 mg/kg aducanumab for up to 36 months. The results are consistent with previously reported analyses from the Phase 1b study and support the design of the ongoing Phase 3 studies of aducanumab for early Alzheimer’s disease.
“We now have up to three years of results from the Phase 1b study of aducanumab and during this time period we continued to observe reduction of the biomarker, amyloid plaque,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “The results also suggest there is a benefit on clinical decline for patients in the Phase 1b study, especially at the highest doses of aducanumab. Our Phase 3 studies of aducanumab are ongoing to determine whether it may be a potential treatment for early Alzheimer’s disease.”
About the Phase 1b study
The Phase 1b study is a randomized, double-blind, placebo-controlled, multiple-dose study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical effects of aducanumab in patients with prodromal or mild Alzheimer’s disease. The study includes fixed dosing at 1, 3, 6 and 10 mg/kg as well as an arm with a titration regimen in which patients received a gradually increased dose of aducanumab until they reach a maximum dose of 10 mg/kg.
The new analyses presented at CTAD include 143 patients in these groups:
- Patients (n=18) initially randomized to titration dosing that gradually increased aducanumab from 1 to 3 to 6 then 10 mg/kg in the 54-week placebo-controlled period and treated up to 24 months
- Patients (n=69) randomized to aducanumab 3, 6 or 10 mg/kg in the 54-week placebo-controlled period and treated up to 36 months
- Patients (n=48) who were randomized to placebo or aducanumab 1 mg/kg in the 54-week placebo-controlled period who were switched to aducanumab 3 mg/kg or to a 3 to 6 mg/kg titration regimen in the LTE and treated up to 24 months
- Patients (n=8) who were randomized to placebo in the 54-week placebo-controlled period who were switched to titration dosing that gradually increased their dose from 1 to 3 to 6 then 10 mg/kg in the LTE and treated up to 12 months
In the Phase 1b LTE, the most commonly reported adverse events were headache, fall and amyloid-related imaging abnormalities (ARIA). Of the 185 patients dosed with aducanumab in the Phase 1b study, 46 patients experienced ARIA-E (edema). There were no new cases of ARIA-E in patients who continued on the same dose of aducanumab.
The incidence of ARIA-E in patients switching from placebo to aducanumab in the LTE was consistent with the incidence reported in the placebo-controlled portion of the Phase 1b study. Six patients experienced more than one episode of ARIA-E. These recurrent events were consistent with other ARIA events reported to date; they were typically asymptomatic, and most patients continued in the study.
Patients who completed the 54-week, placebo-controlled period of the Phase 1b study had the option to continue in the LTE. Of the 196 patients who received placebo or aducanumab treatment in the placebo-controlled period of the Phase 1b study, 143 continued into the LTE. All patients who continued in the LTE were switched to or continued on aducanumab treatment.
Amyloid plaque levels were measured by positron emission tomography (PET) using the standardized uptake value ratio1 (SUVR) and continued to decline in those who remained on treatment for 24 months.
The Clinical Dementia Rating sum of boxes (CDR-SB) and the Mini-Mental State Examination (MMSE), which measure aspects of cognitive and physical function that can be affected by Alzheimer’s disease, were exploratory endpoints of the Phase 1b study. The results of these assessments suggest a continued benefit on the rate of clinical decline during the second year of treatment with aducanumab.
By 24 months, patients treated in the titration treatment group had an expected average dose of 7.6 mg/kg.
At 24 months, the mean change from amyloid plaque levels at the start of the Phase 1b study was:
- -0.170 in those who switched from placebo to aducanumab treatment at 12 months
- -0.149 in those who switched from 1 to 3 mg/kg at 12 months
- -0.197 in the 3 mg/kg treatment group
- -0.280 in the 6 mg/kg treatment group
- -0.322 in the 10 mg/kg treatment group
- -0.271 in the titration treatment group
At 24 months, the average decline from the start of the Phase 1b study on the CDR-SB was:
- 3.25 points in those who switched from placebo to aducanumab treatment at 12 months
- 3.52 points in those who switched from 1 to 3 mg/kg at 12 months
- 2.32 points in the 3 mg/kg treatment group
- 2.98 points in the 6 mg/kg treatment group
- 1.69 points in the 10 mg/kg treatment group
- 2.65 in the titration treatment group
At 24 months, the average decline from the start of the Phase 1b study on the MMSE was:
- 4.28 points in those who switched from placebo to aducanumab treatment at 12 months
- 3.65 points in those who switched from 1 to 3 mg/kg at 12 months
- 2.81 points in the 3 mg/kg treatment group
- 5.20 points in the 6 mg/kg treatment group
- 1.97 points in the 10 mg/kg treatment group
- 1.95 in the titration treatment group
In patients treated up to 36 months, amyloid plaque as measured by PET using SUVR, continued to decrease in a dose- and time-dependent manner, with amyloid plaque levels in the 10 mg/kg fixed-dose treatment group reaching and remaining at a level considered below the quantitative cut-point that discriminates between a positive and negative scan.2
At 36 months, the mean change from amyloid plaque levels at the start of the Phase 1b study was:
- -0.226 in those who switched from placebo to 3 mg/kg or 3-6 mg/kg aducanumab treatment at 12 months
- -0.208 in those who switched from 1 to 3 mg/kg at 12 months
- -0.243 in the 3 mg/kg treatment group
- -0.286 in the 6 mg/kg treatment group
- -0.306 in the 10 mg/kg treatment group
At 36 months, the average decline from the start of the Phase 1b study on the CDR-SB was:
- 5.28 points in those who switched from placebo to 3 mg/kg or 3-6 mg/kg treatment at 12 months
- 6.11 points in those who switched from 1 mg/kg to 3 mg/kg at 12 months
- 3.86 points in the 3 mg/kg treatment group
- 4.49 points in the 6 mg/kg treatment group
- 2.84 points in the 10 mg/kg treatment group
At 36 months, the average decline from the start of the Phase 1b study on the MMSE was:
- 7.98 points in those who switched from placebo to 3 mg/kg or 3-6 mg/kg treatment at 12 months
- 6.35 points in those who switched from 1 mg/kg to 3 mg/kg at 12 months
- 4.83 points in the 3 mg/kg treatment group
- 8.97 points in the 6 mg/kg treatment group
- 4.10 points in the 10 mg/kg treatment group
Data presentations for aducanumab at CTAD are scheduled for:
- November 2, approximately 3:30 p.m. ET: Aducanumab 36-month data from PRIME: A randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease
- November 4, approximately 11:15 a.m. ET: Aducanumab titration dosing regimen: 24-month analysis from PRIME: A randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease
These data presentations will be webcast live. To access the live webcasts, please visit the Investors section of Biogen’s website at www.biogen.com/investors. An archived version of the webcasts will be available following the presentation.
Phase 3 Clinical Studies
Aducanumab is currently being evaluated in two global Phase 3 studies, ENGAGE and EMERGE, which are designed to evaluate its safety and efficacy in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease.
For more information about the Phase 3 studies, including information about participating centers, visit www.ClinicalTrials.gov (NCT02477800 or NCT02484547).
Aducanumab (BIIB037) is an investigational compound being developed for the treatment of Alzheimer’s disease. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.
Aducanumab is thought to target aggregated forms of beta amyloid including soluble oligomers and insoluble fibrils which can form into amyloid plaque in the brain of AD patients. Based on pre-clinical and Phase 1b data to date, treatment with aducanumab has been shown to reduce amyloid plaque levels.
In August 2016 aducanumab was accepted into the European Medicines Agency’s PRIME program. In September 2016 the U.S. Food and Drug Administration accepted aducanumab into its Fast Track program and in April 2017 aducanumab was accepted into the Japanese Ministry of Health, Labour and Welfare’s (MHLW) Sakigake Designation System.
As of October 2017, Biogen and Eisai entered into a global collaboration agreement to jointly develop and commercialize aducanumab.
About Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and behavioral disturbances that eventually result in a person’s inability to perform daily activities. In 2010, it was estimated that 25 million individuals were living with AD worldwide.3 Evidence suggests that pathophysiological changes typically begin years prior to the symptoms that lead to a clinical diagnosis. As the disease progresses, cognitive impairments, behavioral changes and functional disability commonly associated with AD begin to manifest.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissman and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about additional results from the Phase 1b study, and the potential clinical effects of aducanumab. These statements may be identified by words such as “anticipate,” "believe," “could,” “estimate,” "expect," “forecast,” “intend,” "may," "plan," "potential," “possible,” "will," and other words and terms of similar meaning, and are based on our current beliefs and expectations. You should not place undue reliance on these statements or the scientific data presented. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data, analysis, or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, the occurrence of adverse safety events, or we may encounter other unexpected hurdles. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
1 A composite standardized uptake value ratio (SUVR) of six regions of the brain – frontal, parietal, lateral temporal, sensorimotor, anterior and posterior cingulate – was calculated at baseline, at 26, 54, 110 and 166 weeks using whole cerebellum as a reference.
2 Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., Jagust, W. J. and for the Alzheimer's Disease Neuroimaging Initiative (2012), Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol., 72: 578–586. doi:10.1002/ana.23650.
3 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Jefferies Appoints Fred Jallot Head of Fixed Income in Europe19.11.2018 14:52 | Pressemelding
Jefferies today announced the appointment of Fred Jallot as Head of Fixed Income, Europe. He will be based in the firm’s London office starting January 2, 2019 and will report to Fred Orlan, Global Head of Fixed Income at Jefferies. Tim Cronin, who has also served as Head of Fixed Income, Europe, will relinquish this role and continue to serve as President of Jefferies International Limited, Jefferies’ London-based subsidiary. “We are very excited to have Fred Jallot join Jefferies’ leading global fixed income platform,” commented Mr. Orlan. “As a broadly experienced professional in global fixed income, his relationships and leadership will further enhance Jefferies’ growth in this market. This senior hire is an example of Jefferies’ emphasis on enhancing our firm’s European capabilities to serve our regional and global client base,” he added. Mr. Jallot was most recently Global Head of Credit and Asset-Backed Securities in Europe, the Middle East and Africa at Nomura, and previously s
From Niche to Normal – Cannabis Use Becoming More Accepted in the United States19.11.2018 14:47 | Pressemelding
Growing numbers of consumers support the legalization of cannabis in some form and a majority believes it has a positive impact on the economy, according to the newly released 2018 Fall Cannabis Culture Poll, developed jointly by leading global communications agency BCW (Burson Cohn & Wolfe), PSB Research and Civilized, a premium media and lifestyle brand that embraces and highlights modern cannabis culture. A full 83 percent of the poll’s respondents (U.S. adults, cannabis consumers and non-consumers) say they support some form of legalization of cannabis. Sixty-three percent of non-consumers, and 95 percent of cannabis consumers, say legalization has had a positive economic effect on the states where use has been made legal. PSB Research, in partnership with BCW and Civilized, conducted online interviews between September 26 and October 4, 2018 with 1,200 U.S. adults aged 21 and older to explore views on cannabis and its usage and to determine general habits and behaviors of those wh
FRISS: Insurance Carriers Prioritize Fraud Detection and Prevention19.11.2018 13:00 | Pressemelding
Insurance fraud is a global problem. In the U.S. alone, insurance carriers lost over $34 billion in 2017 on fraudulent insurance claims. It’s a global problem with a growing number of technological solutions. Big data analysis and large-scale collaboration are key to fighting insurance fraud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005015/en/ Insurance Fraud Report by FRISS (Graphic: Business Wire) The insurance industry is increasingly focused on preventing fraud through innovative systems, relying on the assistance of specialized vendors to help accomplish the task. The burden of detecting and reducing fraud, therefore, no longer lies with the individual insurer. The 2018 FRISS Insurance Fraud Survey reached over 150 industry professionals and shows a clear picture of the current awareness and challenges of fraud detection and mitigation. Key survey findings show: Increased focus on data quality The quality of
BOC Group´s ADOIT Receives the Highest Score in “Rearchitecting the Enterprise for Transformation” Use Case in Gartner’s 2018 Critical Capabilities for Enterprise Architecture Tools19.11.2018 12:04 | Pressemelding
BOC Group, the leading global provider of Enterprise Management Solutions, is pleased to share its recognition in Gartner’s latest Critical Capabilities Report for Enterprise Architecture Tools*. ADOIT scores within the two highest across all three use cases, while scoring the highest out of eleven tools in “Rearchitecting the Enterprise for Transformation” use case. Christoph Moser, ADOIT product manager comments: "It is satisfying to be recognized by Gartner for our capabilities, which we are certain is due to our unique value proposition and holistic offering. We believe that our scores in this year's Gartner Critical Capabilities for Enterprise Architecture Tools report demonstrate our strength, innovation and continued investment in the agility, flexibility and versatility of our EA portfolio”. The Business Transformation Suite ADOIT supports customers worldwide in the digital transformation of their enterprise, facilitates alignment of their business and IT, and helps generate va
Chubu Centrair International Airport Has Been Ranked 5-Star Airport for Second Time19.11.2018 11:19 | Pressemelding
Chubu Centrair International Airport has been ranked for the second consecutive year as a 5-star Airport*1, the world highest airport rank, in the Regional Airport*2 category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005317/en/ In order to reply to the diversifying needs of the increasing international travellers, Chubu Centrair International Airport is aiming to become an easier to use and a more comfortable airport. In SKYTRAX’s*3 survey, which includes over 500 airport evaluation categories, Chubu Centrair International Airport has ranked specially high in “Airport staff service” and ”Airport cleanness” among other airports. In addition, Chubu Centrair International Airport has been also awarded in SKYTRAX’s “World Airport Awards”, an international airport rating based on client service, as “The World’s Best Regional Airport” (for 4th consecutive year since 2015) and ”Best Regional Airport-Asia” (for 8th conse
Blommer Chocolate to Be Acquired by Fuji Oil Holding19.11.2018 09:03 | Pressemelding
The Blommer Chocolate Company, the largest ingredient chocolate manufacturer in North America and third largest in the world, announced that it has entered into an agreement to be acquired by Fuji Oil Holding, Inc., a global leader in oil and fat ingredients serving the food industry. The sale includes all Blommer business entities, including its four manufacturing operations in North America and one in Shanghai. Blommer is a private, family-owned company; Fuji Oil is publicly traded on the Tokyo Stock Exchange. “For nearly 80 years, our family business has grown to become a major ingredients supplier to most of the iconic brands across a wide variety of food categories,” said Peter Blommer, CEO and third-generation family member. “This is a landmark event in the proud history of Blommer Chocolate Company and begins an exciting new chapter as we look forward to joining a highly respected global leader in Fuji Oil. Our companies share common values and a deep commitment to product quali